← Oncology Approval Tracker

FDA DECISION ·

Turalio

pexidartinib · Daiichi Sankyo

FDA approvalNew dosing regimenTenosynovial giant cell tumor
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A revised 125 mg capsule and recommended 250 mg twice-daily regimen with a low-fat meal for adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitation and unsuitable for improvement with surgery.

LAMPGEN ANALYSIS

Why it matters

The new strength and food instructions change how patients take pexidartinib.

What research teams should watch

Reconcile capsule strength and meal instructions at dispensing and maintain liver safety monitoring and REMS documentation.

PRIMARY RECORDS

Sources